This exclusive research collaboration with Eli Lilly and Company and Verve Therapeutics will focus on advancing Verve's preclinical stage in vivo gene editing program, targeting lipoprotein(a) (LP(a)) for the treatment of Atherosclerotic Cardiovascular Disease, through the completion of Phase 1 clinical development. Lilly will then be responsible for the subsequent development, manufacturing and commercialisation.
Media Contact Information: